Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F21%3AE0108934" target="_blank" >RIV/00843989:_____/21:E0108934 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11110/21:10438215 RIV/65269705:_____/21:00074414 RIV/00064165:_____/21:10438215

Result on the web

<a href="https://jhoonline.biomedcentral.com/track/pdf/10.1186/s13045-021-01071-9.pdf" target="_blank" >https://jhoonline.biomedcentral.com/track/pdf/10.1186/s13045-021-01071-9.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/s13045-021-01071-9" target="_blank" >10.1186/s13045-021-01071-9</a>

Result language

angličtina

Original language name

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Original language description

Therapeutic regimens for previously treated multiple myeloma (MM) may not provide prolonged disease control and are often complicated by significant adverse events, including peripheral neuropathy. In patients with previously treated MM in the Phase 3 BOSTON study, once weekly selinexor, once weekly bortezomib, and 40 mg dexamethasone (XVd) demonstrated a significantly longer median progression-free survival (PFS), higher response rates, deeper responses, a trend to improved survival, and reduced incidence and severity of bortezomib-induced peripheral neuropathy when compared with standard twice weekly bortezomib and 80 mg dexamethasone (Vd). The pre-specified analyses described here evaluated the influence of the number of prior lines of therapy, prior treatment with lenalidomide, prior proteasome inhibitor (PI) therapy, prior immunomodulatory drug therapy, and prior autologous stem cell transplant (ASCT) on the efficacy and safety of XVd compared with Vd. In this 1:1 randomized study, enrolled patients were assigned to receive once weekly oral selinexor (100 mg) with once weekly subcutaneous bortezomib (1.3 mg/m2) and 40 mg per week dexamethasone (XVd) versus standard twice weekly bortezomib and 80 mg per week dexamethasone (Vd). XVd significantly improved PFS, overall response rate, time-to-next-treatment, and showed reduced all grade and grade ? 2 peripheral neuropathy compared with Vd regardless of prior treatments, but the benefits of XVd over Vd were more pronounced in patients treated earlier in their disease course who had either received only one prior therapy, had never been treated with a PI, or had prior ASCT. Treatment with XVd improved outcomes as compared to Vd regardless of prior therapies as well as manageable and generally reversible adverse events. XVd was associated with clinical benefit and reduced peripheral neuropathy compared to standard Vd in previously treated MM. These results suggest that the once weekly XVd regimen may be optimally a...

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30205 - Hematology

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of hematology & oncology

ISSN

1756-8722

e-ISSN

1756-8722

Volume of the periodical

14

Issue of the periodical within the volume

59)

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

1-5

UT code for WoS article

000640253700001

EID of the result in the Scopus database

2-s2.0-85104307966